In conclusion, although CCL5 expression is associated to a better outcome in breast cancer, particularly in TNBC, TILs assessment remains the stronger and more significant prognostic immunological marker although characterization of cellular states of TILs should provide a more precise prognostic biomarker. Here, CCL5 is linked to breast cancer.